

2020/21 Month 12 Financial Performance

Author: Tarun Basra - Head of Financial Performance

Sponsor: Simon Lazarus - Chief Financial Officer

Trust Board paper I5

Purpose of Report:

This paper is for:	Description	Select (X)
Decision	To formally receive a report and approve its recommendations OR a particular course of action	
Discussion	To discuss, in depth, a report noting its implications without formally approving a recommendation or action	X
Assurance	To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan	
Noting	For noting without the need for discussion	

Previous Consideration:

Meeting	Date	Please clarify the purpose of the paper to that meeting using the categories above
CMG Board (specify which CMG)		
FRB	28.04.21	Discussion
FIC	29.04.21	Discussion
Trust Board		

Executive Summary

Context:

This paper updates the Trust Board on the financial performance of the Trust at Month 12 of 2020/21.

To support the Trust during Covid-19, NHSE&I are providing an upfront Top Up payment. This was estimated from the Trust's underlying financial position.

Questions:

1. What is the financial performance for the period ending 31th March 2021?

The actual position including Top Up funding is a £16.4m surplus, which is £10.6m adverse to forecast.

2. What are the main issues of note in the Month 7-12 financial performance?

The main issues are as follows:

- £10.92m provision made in month 12 relating to the repayment of 19/20 quarter 1 to quarter 2 Provider Sustainability Fund (PSF) and the Financial Recovery Fund (FRF).
- National funding has been received for the increase in annual leave provision of £8.6m, the Flowers legal case of £2.7m and £28.5m relating to the NHS Pension Scheme employer contribution.
- A total of £10.3m provisions were recognised in the month 12 position in line with the forecast.
- The Trust is continuing to review 2019/20 financial position as part of the audit process and that there remains a significant risk that this will impact on the 2020/21 financial position.

Input Sought:

The Trust Board is asked to **note**:

- **Note** the Month 12 (2020/21) reported financial position.
- **Note** the continuing review of 2019/20 financial position as part of the audit process and there remains a significant risk that this will impact on the 2020/21 financial position.

For Reference:

This report relates to the following UHL quality and supporting priorities:

1. Quality priorities

Safe, surgery and procedures
Safely and timely discharge
Improved Cancer pathways
Streamlined emergency care
Better care pathways
Ward accreditation

Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

2. Supporting priorities

People strategy implementation
Estate investment and reconfiguration
e-Hospital
More embedded research
Better corporate services
Quality strategy development

Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

3. Equality Impact Assessment and Patient and Public Involvement considerations

- What was the outcome of your Equality Impact Assessment (EIA)? **Not applicable**
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required. **None required**
- How did the outcome of the EIA influence your Patient and Public Involvement? **Not applicable**
- If an EIA was not carried out, what was the rationale for this decision? **Not applicable**

4. Risk and Assurance

Risk Reference:

Does this paper reference a risk event?	Select (X)	Risk Description:
Strategic: Does this link to a Principal Risk on the BAF?	X	Principal Risk 4 – Financial Sustainability
Organisational: Does this link to an Operational/Corporate Risk on Datix Register		
New Risk identified in paper: What type and description ?		
None		

5. Scheduled date for the **next paper** on this topic: 3 June 2021

6. Executive Summaries should not exceed **5 sides** [My paper does/~~does not~~ comply]



Financial Performance Report

March 2021

One team shared values



Exec summary

Caring at its best


- The Trust has reported a year end surplus of £16.4m. The year end position is £10.6m adverse to the forecast (Page 7 breaks this down by category of expenditure). The Trust is continuing to review 2019/20 financial position as part of the audit process and there remains a significant risk that this will impact on the 2020/21 financial position.
- The driver for the adverse financial performance against forecast is due to a £10.9m provision made in month 12 relating to the repayment of 19/20 quarter 1 to quarter 2 Provider Sustainability Fund (PSF) and the Financial Recovery Fund (FRF) as per guidance provided by NHSEI post month 11 forecast submission.
- National funding has been provided for the increase in annual leave provision of £8.6m, the Flowers legal case of £2.7m and £28.5m relating to the 6.3% NHS Pension Scheme employer contribution. These items have been included in the month 12 expenditure position offset by income.
- A total of £10.3m provisions were recognised in the month 12 position as per the forecast. These provisions include Section 106 costs (£2.2m), VAT liability (£1.9m), working time directive (£1.4m), drugs expenditure (£1.4m), review of assets under construction/additional depreciation (£3.2m) and these will be subject to review within the year end accounts process and audit.
- The financial improvement continued to be consistent with current expenditure trends. This included lower recruitment levels than planned, reduced restoration and recovery activity, reduced winter fill due to staff shortages, increased income from Heath Education England, and significant underspends in non-pay as a result of reduced activity (Page 10 shows the detail by category).

Exec summary


- The Trust has reported a risk adjusted end of year CIP cash releasing position of £8.8m against an £8m CIP target. (Page 12-13 details CIP delivery).
- c£2m non-recurrent expenditure committed in 2020/21 related to approved non-recurrent expenditure. This included in the main infusion pumps, defibrillators, kit and equipment to reduce theatre cancelations, Pathology equipment and Imaging equipment.
- The Trust's cash position at the end of month 12 was £90m. After adjusting for deferred income, the Trust's underlying cash position was c£88m.
- Capital payments accounted for in March will accelerate in Q1 of 2021/22 for payments, resulting in further reduction to the underlying level of cash.
- Although the Trust currently remains in a very healthy cash position this will be challenged during 2021/22, as the NHS emerges out of Covid-19 and the NHS as a whole returns to a normalised funding regime.

Key highlights (2/2)


Pay Run Rate




Agency Run Rate




Plan vs Actual - Substantive Pay Spend




Plan vs Actual - Agency Pay Spend



WLIs – Restoration and Recovery



WTE Run Rate as per CMGs



Summary financial position (M7-M12)

	In month			Plan (M7 - M12)			FOT		
	Forecast	Actual	Variance	Plan	Actual	Variance	Forecast (M11)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Patient care income	78,416	80,555	2,139	469,522	477,753	8,231	475,614	477,753	2,139
Other income	30,337	72,277	41,940	143,964	201,578	57,614	159,638	201,578	41,940
Total income	108,753	152,832	44,078	613,485	679,330	65,845	635,252	679,330	44,078
Pay costs	(63,064)	(101,588)	(38,524)	(387,571)	(404,660)	(17,089)	(366,136)	(404,660)	(38,524)
Non-pay costs	(47,491)	(64,814)	(17,323)	(223,241)	(227,326)	(4,084)	(210,003)	(227,326)	(17,323)
Total costs	(110,555)	(166,402)	(55,847)	(610,813)	(631,986)	(21,173)	(576,139)	(631,986)	(55,847)
EBITDA	(1,802)	(13,570)	(11,768)	2,673	47,345	44,672	59,113	47,345	(11,768)
Non-operating costs	(5,380)	(4,636)	744	(25,223)	(26,635)	(1,413)	(27,379)	(26,635)	744
Retained surplus / (deficit)	(7,182)	(18,207)	(11,024)	(22,550)	20,709	43,259	31,734	20,709	(11,024)
Donated assets	(1,559)	(1,105)	454	437	(4,336)	(4,773)	(4,790)	(4,336)	454
Net surplus / (deficit)	(8,741)	(19,312)	(10,570)	(22,113)	16,374	38,486	26,944	16,374	(10,570)
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus/(deficit) against control total	(8,741)	(19,312)	(10,570)	(22,113)	16,374	38,486	26,944	16,374	(10,570)

Comments - FOT

Over performance linked to £1.9mF Excluded Drugs and Devices in relation to specialised drugs.

£28.5mF relating NHS Pension Scheme employer contribution, £8.6mF 20/21 annual leave provision and £2.7mF accrual relating to Flowers legal case.

£28.5mA relating NHS Pension Scheme employer contribution, £8.6mA 20/21 annual leave provision and £2.7mA accrual relating to Flowers legal case.

£10.9mA relating to 19/20 PSF/FRF Repayment, £2.6mA year end stock movement, £1mA Excluded Drugs and Devices and c. £1mA activity consumables.

Appendix 1: total 2020/21 forecast (M7-M12)

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	In month			FOT		
	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21	Full year	Forecast	Actual	Variance	Forecast (M11)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
Patient care income	80,313	80,160	78,887	80,013	77,826	80,555	477,753	78,416	80,555	2,139	475,614	477,753	2,139
Other income	22,967	28,804	25,746	26,126	25,657	72,277	201,578	30,337	72,277	41,940	159,638	201,578	41,940
Total income	103,280	108,964	104,632	106,139	103,484	152,832	679,330	108,753	152,832	44,078	635,252	679,330	44,078
Pay costs	(60,748)	(59,981)	(61,647)	(60,218)	(60,478)	(101,588)	(404,660)	(63,064)	(101,588)	(38,524)	(366,136)	(404,660)	(38,524)
Non-pay costs	(35,453)	(35,376)	(31,620)	(28,901)	(31,162)	(64,814)	(227,326)	(47,491)	(64,814)	(17,323)	(210,003)	(227,326)	(17,323)
Total costs	(96,201)	(95,356)	(93,267)	(89,120)	(91,640)	(166,402)	(631,986)	(110,555)	(166,402)	(55,847)	(576,139)	(631,986)	(55,847)
EBITDA	7,079	13,608	11,365	17,019	11,844	(13,570)	47,345	(1,802)	(13,570)	(11,768)	59,113	47,345	(11,768)
Non-operating costs	(4,740)	(3,629)	(3,458)	(6,522)	(3,649)	(4,636)	(26,635)	(5,380)	(4,636)	744	(27,379)	(26,635)	744
Retained surplus / (deficit)	2,339	9,978	7,907	10,497	8,194	(18,207)	20,709	(7,182)	(18,207)	(11,024)	31,734	20,709	(11,024)
Donated assets	66	(2,593)	50	(308)	(446)	(1,105)	(4,336)	(1,559)	(1,105)	454	(4,790)	(4,336)	454
Net surplus / (deficit)	2,405	7,385	7,957	10,189	7,748	(19,312)	16,374	(8,741)	(19,312)	(10,570)	26,944	16,374	(10,570)
Provider sustainability fund	0	0	0	0	0	0	0	0	0	0	0	0	0
Surplus/(deficit) against control total	2,405	7,385	7,957	10,189	7,748	(19,312)	16,374	(8,741)	(19,312)	(10,570)	26,944	16,374	(10,570)

The points below summarise the key movement to the actual surplus of £16.4m from the forecast of £26.9m:

- In month £10.92m provision relating to repayment of 19/20 Provider Sustainability Fund (PSF) and the Financial Recovery Fund (FRF) outside of forecast at month 11.
- £352k favourable relating to provisions and CMG/Directorates forecast movement, reflecting assumptions of continued reduced activity as seen in January to March 2021.

Appendix 2: break down of total forecast (1/3)

	In month			FOT		
	Forecast	Actual	Variance	Forecast (M11)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Baseline forecast						
Patient care income	78,416	80,555	2,139	475,614	477,753	2,139
Other income	25,810	67,845	42,035	134,484	176,519	42,035
Total income	104,226	148,400	44,174	610,098	654,272	44,174
Pay costs	(62,173)	(101,104)	(38,931)	(362,058)	(400,989)	(38,931)
Non pay costs	(46,049)	(63,607)	(17,558)	(206,636)	(224,195)	(17,558)
Total costs	(108,222)	(164,711)	(56,489)	(568,694)	(625,183)	(56,489)
EBITDA	(3,996)	(16,311)	(12,316)	41,404	29,088	(12,316)
Non-operating costs	(5,380)	(4,636)	744	(27,379)	(26,635)	744
Retained surplus / (deficit)	(9,376)	(20,948)	(11,571)	14,024	2,453	(11,571)
Donated assets	(1,559)	(1,105)	454	(4,790)	(4,336)	454
Net deficit	(10,936)	(22,053)	(11,117)	9,234	(1,883)	(11,117)
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	(10,936)	(22,053)	(11,117)	9,234	(1,883)	(11,117)
COVID						
Patient care income	0	0	0	0	0	0
Other income	4,457	4,223	(234)	24,404	24,171	(234)
Total income	4,457	4,223	(234)	24,404	24,171	(234)
Pay costs	(921)	(781)	139	(4,231)	(4,091)	139
Non pay costs	(1,393)	(1,407)	(14)	(4,459)	(4,473)	(14)
Total costs	(2,313)	(2,188)	125	(8,690)	(8,564)	125
EBITDA	2,144	2,035	(109)	15,715	15,606	(109)
Non-operating costs	0	0	0	0	0	0
Retained surplus / (deficit)	2,144	2,035	(109)	15,715	15,606	(109)
Donated assets	0	0	0	0	0	0
Net deficit	2,144	2,035	(109)	15,715	15,606	(109)
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	2,144	2,035	(109)	15,715	15,606	(109)

Appendix 2: break down of total forecast (2/3)

	In month			FOT		
	Forecast	Actual	Variance	Forecast (M11)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Restoration and recovery						
Patient care income	0	0	0	0	0	0
Other income	0	0	0	0	0	0
Total income	0	0	0	0	0	0
Pay costs	(263)	(142)	121	(1,648)	(1,527)	121
Non pay costs	(569)	(442)	128	(2,804)	(2,677)	128
Total costs	(832)	(584)	249	(4,452)	(4,203)	249
EBITDA	(832)	(584)	249	(4,452)	(4,203)	249
Non-operating costs	0	0	0	0	0	0
Retained surplus / (deficit)	(832)	(584)	249	(4,452)	(4,203)	249
Donated assets	0	0	0	0	0	0
Net deficit	(832)	(584)	249	(4,452)	(4,203)	249
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	(832)	(584)	249	(4,452)	(4,203)	249
Winter pressures						
Patient care income	0	0	0	0	0	0
Other income	0	0	0	0	0	0
Total income	0	0	0	0	0	0
Pay costs	(392)	(335)	57	(1,669)	(1,612)	57
Non pay costs	(44)	(26)	18	(361)	(342)	18
Total costs	(437)	(361)	76	(2,030)	(1,954)	76
EBITDA	(437)	(361)	76	(2,030)	(1,954)	76
Non-operating costs	0	0	0	0	0	0
Retained surplus / (deficit)	(437)	(361)	76	(2,030)	(1,954)	76
Donated assets	0	0	0	0	0	0
Net deficit	(437)	(361)	76	(2,030)	(1,954)	76
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	(437)	(361)	76	(2,030)	(1,954)	76

Appendix 2: break down of total forecast (3/3)

	In month			FOT		
	Forecast	Actual	Variance	Forecast (M11)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
CIP savings						
Patient care income	0	0	0	0	0	0
Other income	70	209	138	750	888	138
Total income	70	209	138	750	888	138
Pay costs	685	775	89	3,469	3,558	89
Non pay costs	564	667	103	4,258	4,361	103
Total costs	1,249	1,442	193	7,727	7,919	193
EBITDA	1,320	1,651	331	8,477	8,808	331
Non-operating costs	0	0	0	0	0	0
Retained surplus / (deficit)	1,320	1,651	331	8,477	8,808	331
Donated assets	0	0	0	0	0	0
Net deficit	1,320	1,651	331	8,477	8,808	331
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	1,320	1,651	331	8,477	8,808	331
Total forecast						
Patient Care Income	78,416	80,555	2,139	475,614	477,753	2,139
Other Income	30,337	72,277	41,940	159,638	201,578	41,940
Total Income	108,753	152,832	44,078	635,252	679,330	44,078
Pay costs	(63,064)	(101,588)	(38,524)	(366,136)	(404,660)	(38,524)
Non pay costs	(47,491)	(64,814)	(17,323)	(210,003)	(227,326)	(17,323)
Total costs	(110,555)	(166,402)	(55,847)	(576,139)	(631,986)	(55,847)
EBITDA	(1,802)	(13,570)	(11,768)	59,113	47,345	(11,768)
Non-operating costs	(5,380)	(4,636)	744	(27,379)	(26,635)	744
Retained surplus / (deficit)	(7,182)	(18,207)	(11,024)	31,734	20,709	(11,024)
Donated assets	(1,559)	(1,105)	454	(4,790)	(4,336)	454
Net deficit	(8,741)	(19,312)	(10,570)	26,944	16,374	(10,570)
Provider sustainability fund	0	0	0	0	0	0
Surplus / (deficit) against control total	(8,741)	(19,312)	(10,570)	26,944	16,374	(10,570)

Appendix 3 – forecast outturn analysis

	M7-M12 Forecast @ M11 £'000							M7-12 Actuals @ M12 £'000							M7-M12 - Actuals/FOT Variance @ M12 £'000						
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
NHS Patient Income	0	0	0	0	0	475,614	475,614	0	0	0	0	0	477,753	477,753	0	0	0	0	0	2,139	2,139
Other Operating Income	24,404	0	0	236	514	134,484	159,638	24,171	0	0	239	649	176,519	201,578	(234)	0	0	3	135	42,035	41,940
Total Income	24,404	0	0	236	514	610,098	635,252	24,171	0	0	239	649	654,272	679,330	(234)	0	0	3	135	44,174	44,078
Non Agency Pay	(3,201)	(1,334)	(1,157)	894	2,202	(352,596)	(355,192)	(3,060)	(1,213)	(1,087)	934	2,267	(391,736)	(393,896)	141	122	70	39	64	(39,141)	(38,705)
Agency Pay	(1,029)	(313)	(512)	334	38	(9,462)	(10,945)	(1,031)	(314)	(525)	320	38	(9,252)	(10,764)	(1)	(0)	(13)	(14)	0	210	181
Non-pay	(4,459)	(2,804)	(361)	2,343	1,914	(206,636)	(210,003)	(4,473)	(2,677)	(342)	2,705	1,656	(224,195)	(227,326)	(14)	128	18	362	(259)	(17,558)	(17,323)
Total Operating Costs	(8,690)	(4,452)	(2,030)	3,572	4,155	(568,694)	(576,139)	(8,564)	(4,203)	(1,954)	3,959	3,960	(625,183)	(631,986)	125	249	76	387	(194)	(56,489)	(55,847)
EBITDA	15,715	(4,452)	(2,030)	3,808	4,669	41,404	59,113	15,606	(4,203)	(1,954)	4,198	4,609	29,088	47,345	(109)	249	76	391	(59)	(12,316)	(11,768)
Non Operating Costs	0	0	0	0	0	(27,379)	(27,379)	0	0	0	0	0	(26,635)	(26,635)	0	0	0	0	0	744	744
Retained Surplus/(Deficit)	15,715	(4,452)	(2,030)	3,808	4,669	14,024	31,734	15,606	(4,203)	(1,954)	4,198	4,609	2,453	20,709	(109)	249	76	391	(59)	(11,571)	(11,024)
Donated Assets	0	0	0	0	0	(4,790)	(4,790)	0	0	0	0	0	(4,336)	(4,336)	0	0	0	0	0	454	454
Net Surplus/(Deficit)	15,715	(4,452)	(2,030)	3,808	4,669	9,234	26,944	15,606	(4,203)	(1,954)	4,198	4,609	(1,883)	16,374	(109)	249	76	391	(59)	(11,117)	(10,570)

	M12 YTD Forecast @ M11 £'000							YTD Actuals @ M12 £'000							YTD - Actuals/FOT @ M12 Variance £'000						
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
NHS Patient Income	0	0	0	0	0	475,614	475,614	0	0	0	0	0	477,753	477,753	0	0	0	0	0	2,139	2,139
Other Operating Income	24,404	0	0	236	514	134,484	159,638	24,171	0	0	239	649	176,519	201,578	(234)	0	0	3	135	42,035	41,940
Total Income	24,404	0	0	236	514	610,098	635,252	24,171	0	0	239	649	654,272	679,330	(234)	0	0	3	135	44,174	44,078
Non Agency Pay	(3,201)	(1,334)	(1,157)	894	2,202	(352,596)	(355,192)	(3,060)	(1,213)	(1,087)	934	2,267	(391,736)	(393,896)	141	122	70	39	64	(39,141)	(38,705)
Agency Pay	(1,029)	(313)	(512)	334	38	(9,462)	(10,945)	(1,031)	(314)	(525)	320	38	(9,252)	(10,764)	(1)	(0)	(13)	(14)	0	210	181
Non-pay	(4,459)	(2,804)	(361)	2,343	1,914	(206,636)	(210,003)	(4,473)	(2,677)	(342)	2,705	1,656	(224,195)	(227,326)	(14)	128	18	362	(259)	(17,558)	(17,323)
Total Operating Costs	(8,690)	(4,452)	(2,030)	3,572	4,155	(568,694)	(576,139)	(8,564)	(4,203)	(1,954)	3,959	3,960	(625,183)	(631,986)	125	249	76	387	(194)	(56,489)	(55,847)
EBITDA	15,715	(4,452)	(2,030)	3,808	4,669	41,404	59,113	15,606	(4,203)	(1,954)	4,198	4,609	29,088	47,345	(109)	249	76	391	(59)	(12,316)	(11,768)
Non Operating Costs	0	0	0	0	0	(27,379)	(27,379)	0	0	0	0	0	(26,635)	(26,635)	0	0	0	0	0	744	744
Retained Surplus/(Deficit)	15,715	(4,452)	(2,030)	3,808	4,669	14,024	31,734	15,606	(4,203)	(1,954)	4,198	4,609	2,453	20,709	(109)	249	76	391	(59)	(11,571)	(11,024)
Donated Assets	0	0	0	0	0	(4,790)	(4,790)	0	0	0	0	0	(4,336)	(4,336)	0	0	0	0	0	454	454
Net Surplus/(Deficit)	15,715	(4,452)	(2,030)	3,808	4,669	9,234	26,944	15,606	(4,203)	(1,954)	4,198	4,609	(1,883)	16,374	(109)	249	76	391	(59)	(11,117)	(10,570)

	M12 Forecast @ M11 £'000							M12 Actuals £'000							M12 FOT Variance £'000							
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	
NHS Patient Income	0	0	0	0	0	78,416	78,416	0	0	0	0	0	80,555	80,555	0	0	0	0	0	2,139	2,139	
Non NHS Patient Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Income	4,457	0	0	23	47	30,337	30,337	4,223	0	0	27	182	72,277	72,277	(234)	0	0	3	135	42,035	41,940	
Total Income	4,457	0	0	23	47	104,226	108,753	4,223	0	0	27	182	148,400	152,832	(234)	0	0	3	135	44,174	44,078	
Non Agency Pay	(708)	(198)	(261)	142	463	(61,089)	(61,089)	(567)	(77)	(191)	181	527	(99,794)	(99,794)	141	122	70	39	64	(39,141)	(38,705)	
Agency Pay	(213)	(65)	(132)	81	0	(1,975)	(1,975)	(214)	(66)	(145)	67	0	(1,794)	(1,794)	(1)	(0)	(13)	(14)	0	210	181	
Non-pay	(1,393)	(569)	(44)	303	261	(47,491)	(47,491)	(1,407)	(442)	(26)	665	2	(64,814)	(64,814)	(14)	128	18	362	(259)	(17,558)	(17,323)	
Total Operating Costs	(2,313)	(832)	(437)	526	723	(108,222)	(110,555)	(2,188)	(584)	(361)	913	529	(164,711)	(166,402)	125	249	76	387	(194)	(56,489)	(55,847)	
EBITDA	2,144	(832)	(437)	549	771	(3,996)	(1,802)	2,035	(584)	(361)	940	711	(16,311)	(13,570)	(109)	249	76	391	(59)	(12,316)	(11,768)	
Non Operating Costs	0	0	0	0	0	(5,380)	(5,380)	0	0	0	0	0	(4,636)	(4,636)	0	0	0	0	0	744	744	
Retained Surplus/(Deficit)	2,144	(832)	(437)	549	771	(9,376)	(7,182)	2,035	(584)	(361)	940	711	(20,948)	(18,207)	(109)	249	76	391	(59)	(11,571)	(11,024)	
Donated Assets	0	0	0	0	0	(1,559)	(1,559)	0	0	0	0	0	(1,105)	(1,105)	0	0	0	0	0	454	454	
Net Surplus/(Deficit)	2,144	(832)	(437)	549	771	(10,936)	(8,741)	2,035	(584)	(361)	940	711	(22,053)	(19,312)	(109)	249	76	391	(59)	(11,117)	(10,570)	

Appendix 4: WTE, pay and WLI breakdown

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	In month		
	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21	Full year	Forecast M12	Actual M12	Variance
Baseline forecast																
Substantive	13921	13948	13881	13865	13908	13847	13831	13816	13861	13840	13955	14125	166799	13964	14125	161
Bank	564	504	513	634	712	710	748	646	590	573	593	595	7382	602	595	-7
Agency	225	232	298	144	309	307	312	329	303	340	347	314	3459	359	314	-45
Sub-total	14710	14685	14691	14643	14929	14865	14890	14791	14755	14753	14895	15035	177641	14925	15035	110
COVID																
Substantive	0	0	28	41	10	6	12	9	8	8	13	12	148	76	12	-64
Bank	97	94	64	47	35	19	31	59	65	99	122	106	838	65	106	41
Agency	17	13	23	24	10	22	30	40	63	52	60	50	404	65	50	-15
Sub-total	113	107	116	112	55	47	73	108	136	159	196	168	1390	206	168	-38
Restoration and recovery																
Substantive	0	0	0	0	0	0	20	18	18	10	10	17	93	13	17	4
Bank	0	0	0	0	0	0	16	7	12	1	2	2	39	13	2	-11
Agency	0	0	0	0	0	0	0	2	4	11	11	12	40	14	12	-2
Sub-total	0	0	0	0	0	0	36	27	33	22	23	31	172	40	31	-9
Winter pressures																
Substantive	0	0	0	0	0	0	0	15	17	21	20	16	90	18	16	-2
Bank	0	0	0	0	0	0	1	23	41	44	80	72	261	80	72	-8
Agency	0	0	0	0	0	0	5	10	19	17	45	44	141	44	44	0
Sub-total	0	0	0	0	0	0	7	49	78	82	145	132	492	143	132	-10
CIP savings																
Substantive	0	0	0	0	0	0	-7	-7	-11	-9	-10	-9	-55	-8	-9	-1
Bank	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Agency	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sub-total	0	0	0	0	0	0	-7	-7	-11	-9	-10	-9	-55	-8	-9	-1
Total																
Substantive	13921	13948	13909	13907	13918	13853	13855	13850	13894	13871	13988	14161	167075	14062	14161	98
Bank	661	598	577	681	748	729	795	734	708	717	797	775	8521	760	775	15
Agency	241	245	321	167	319	329	347	382	388	420	463	421	4045	483	421	-62
Total	14823	14791	14807	14755	14985	14912	14998	14966	14990	15007	15248	15357	179640	15305	15357	51

Appendix 5: update on CIP (M7-M12) (1/2)

Planned	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	1,082	1,029	1,044	1,509	1,256	2,077	7,998	7,998
Non Cash Releasing / Clinical Productivity	24	19	14	19	19	19	115	167
Total All	1,106	1,048	1,059	1,528	1,275	2,096	8,112	8,165






Actual / Forecast	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	685	1,333	1,217	1,942	1,979	1,651	8,808	8,808
Non Cash Releasing / Clinical Productivity	363	282	290	290	255	282	1,763	1,837
Total All	1,049	1,616	1,507	2,232	2,233	1,933	10,570	10,645

Actual / Forecast (Risk Adjusted)	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	685	1,333	1,217	1,942	1,979	1,651	8,808	8,808
Non Cash Releasing / Clinical Productivity	363	282	290	290	255	282	1,763	1,837
Total All	1,049	1,616	1,507	2,232	2,233	1,933	10,570	10,645

The risk adjusted schemes figures are valued in the above table at 100% (Green), 25% (Amber) and 0% (Red)

Variance to Plan (Risk Adjusted)	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	(397)	304	173	434	723	(426)	810	810
Non Cash Releasing / Clinical Productivity	339	264	276	271	235	263	1,648	1,670
Total All	(57)	568	448	705	958	(163)	2,458	2,480

Appendix 5: update on CIP (2/2)



Appendix 6: activity and SLA income

Point of delivery	FY19/20 YTD (M7-12)		Activity YTD (M7-12)			Income YTD £000 (M7-12)			Income forecast £000 (M7-12)		
	Activity	Income £000	Plan	Actual	Variance	Plan	Actual	Variance	Previous Month Forecast	Outturn	Variance
Emergency department	123,606	19,365	120,779	93,395	(27,384)	20,109	15,365	(4,744)	15,922	15,365	(557)
Day cases	51,884	30,114	42,925	39,533	(3,392)	26,188	20,765	(5,424)	20,561	20,765	203
Elective	9,293	38,424	7,675	5,541	(2,134)	33,913	21,701	(12,212)	23,478	21,701	(1,776)
Non elective	60,496	135,002	57,960	52,779	(5,180)	134,896	117,809	(17,086)	117,411	117,809	398
Outpatient – first	127,051	24,506	119,446	96,100	(23,346)	23,417	15,899	(7,518)	15,992	15,899	(93)
Outpatient – follow up	309,566	26,516	284,218	284,781	563	26,253	18,480	(7,773)	18,678	18,480	(198)
Outpatient procedures	78,458	11,150	60,966	53,031	(7,935)	9,498	8,401	(1,097)	8,054	8,401	348
Critical care services	30,716	30,675	27,562	25,379	(2,183)	28,286	26,035	(2,251)	25,458	26,035	577
Renal dialysis and transplant	96,321	15,820	95,727	96,126	399	15,472	14,832	(640)	14,934	14,832	(102)
Other central SLA income	4,243,524	78,225	4,220,683	3,862,933	(357,750)	102,811	157,102	54,290	155,742	157,102	1,359
Excluded devices & Medicines	18,401	51,482	-	18,592	18,592	48,680	61,365	12,685	59,385	61,365	1,979
Total SLA income (before fines)	5,149,315	461,278	5,037,941	4,628,190	(409,751)	469,523	477,752	8,230	475,614	477,752	2,138
Fines and penalties	-	(429)	-	-	-	-	-	-	-	-	-
Total SLA income (after fines)	5,149,315	460,850	5,037,941	4,628,190	(409,751)	469,523	477,752	8,230	475,614	477,752	2,138

As a result of the interim financial arrangements in place during COVID, all NHS providers are paid a block payment from commissioners at values set nationally by NHSE/I. The Trust has aligned its patient care income plan with these block payments, although there are still some variances to the plan which are due to variable elements within the block contract and patient care income which is not included within the block amount.

Although income is blocked, the Trust continues to report significant reductions in activity due to COVID.

Elective services are continuing to see the impact of Covid-19, with Critical Care services being impacted to a lesser degree. Renal Dialysis and Transplant is the only service with activity in line with last year's performance.

Appendix 7: financial performance by CMG and directorate (1/2)

	Trust overall					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	635,252	679,330	44,078	635,252	679,330	44,078
Total Pay	(366,136)	(404,660)	(38,524)	(366,136)	(404,660)	(38,524)
Non Pay	(210,003)	(227,326)	(17,323)	(210,003)	(227,326)	(17,323)
Total Expenditure	(576,139)	(631,986)	(55,847)	(576,139)	(631,986)	(55,847)
EBITDA	59,113	47,345	(11,768)	59,113	47,345	(11,768)
Non Operating Costs	(27,379)	(26,635)	744	(27,379)	(26,635)	744
Donated Assets	(4,790)	(4,336)	454	(4,790)	(4,336)	454
Net Surplus/(Deficit)	26,944	16,374	(10,570)	26,944	16,374	(10,570)

	CHUGGS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	97,798	98,066	268	97,798	98,066	268
Total Pay	(32,980)	(32,932)	48	(32,980)	(32,932)	48
Non Pay	(37,505)	(37,834)	(329)	(37,505)	(37,834)	(329)
Total Expenditure	(70,485)	(70,766)	(281)	(70,485)	(70,766)	(281)
EBITDA	27,313	27,300	(13)	27,313	27,300	(13)

	CSI					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	34,478	34,704	226	34,478	34,704	226
Total Pay	(50,911)	(50,799)	112	(50,911)	(50,799)	112
Non Pay	(8,180)	(9,154)	(974)	(8,180)	(9,154)	(974)
Total Expenditure	(59,092)	(59,953)	(862)	(59,092)	(59,953)	(862)
EBITDA	(24,613)	(25,249)	(635)	(24,613)	(25,249)	(635)

	ESM					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	106,040	106,265	225	106,040	106,265	225
Total Pay	(60,664)	(60,904)	(240)	(60,664)	(60,904)	(240)
Non Pay	(24,083)	(24,938)	(855)	(24,083)	(24,938)	(855)
Total Expenditure	(84,747)	(85,843)	(1,095)	(84,747)	(85,843)	(1,095)
EBITDA	21,293	20,423	(870)	21,293	20,423	(870)

	ITAPS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	21,070	21,173	103	21,070	21,173	103
Total Pay	(40,205)	(39,278)	928	(40,205)	(39,278)	928
Non Pay	(11,277)	(11,966)	(689)	(11,277)	(11,966)	(689)
Total Expenditure	(51,482)	(51,243)	239	(51,482)	(51,243)	239
EBITDA	(30,413)	(30,070)	342	(30,413)	(30,070)	342

	MSS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	58,596	58,725	129	58,596	58,725	129
Total Pay	(28,789)	(28,579)	210	(28,789)	(28,579)	210
Non Pay	(9,884)	(10,312)	(428)	(9,884)	(10,312)	(428)
Total Expenditure	(38,673)	(38,891)	(218)	(38,673)	(38,891)	(218)
EBITDA	19,923	19,834	(89)	19,923	19,834	(89)

Appendix 7: financial performance by CMG and directorate (2/2)

	RRCV					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	107,239	108,794	1,555	107,239	108,794	1,555
Total Pay	(44,480)	(44,321)	159	(44,480)	(44,321)	159
Non Pay	(30,335)	(31,891)	(1,556)	(30,335)	(31,891)	(1,556)
Total Expenditure	(74,815)	(76,212)	(1,397)	(74,815)	(76,212)	(1,397)
EBITDA	32,424	32,582	158	32,424	32,582	158

	W&C					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	91,888	92,491	604	91,888	92,491	604
Total Pay	(48,217)	(48,198)	18	(48,217)	(48,198)	18
Non Pay	(20,493)	(20,471)	22	(20,493)	(20,471)	22
Total Expenditure	(68,710)	(68,669)	40	(68,710)	(68,669)	40
EBITDA	23,178	23,822	644	23,178	23,822	644

	Estates and facilities					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	7,499	8,234	735	7,499	8,234	735
Total Pay	(20,844)	(20,858)	(14)	(20,844)	(20,858)	(14)
Non Pay	(18,048)	(18,787)	(739)	(18,048)	(18,787)	(739)
Total Expenditure	(38,892)	(39,645)	(753)	(38,892)	(39,645)	(753)
EBITDA	(31,393)	(31,411)	(18)	(31,393)	(31,411)	(18)

	Corporate					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	10,375	11,004	629	10,375	11,004	629
Total Pay	(20,724)	(20,804)	(80)	(20,724)	(20,804)	(80)
Non Pay	(26,301)	(27,528)	(1,227)	(26,301)	(27,528)	(1,227)
Total Expenditure	(47,025)	(48,332)	(1,307)	(47,025)	(48,332)	(1,307)
EBITDA	(36,650)	(37,328)	(678)	(36,650)	(37,328)	(678)

	R&I					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	18,560	19,756	1,197	18,560	19,756	1,197
Total Pay	(7,760)	(7,782)	(23)	(7,760)	(7,782)	(23)
Non Pay	(9,454)	(9,465)	(11)	(9,454)	(9,465)	(11)
Total Expenditure	(17,214)	(17,247)	(33)	(17,214)	(17,247)	(33)
EBITDA	1,346	2,509	1,164	1,346	2,509	1,164

	Alliance					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M12)	Outturn (M12)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	10,952	10,948	(4)	10,952	10,948	(4)
Total Pay	(5,786)	(5,783)	4	(5,786)	(5,783)	4
Non Pay	(4,329)	(4,141)	188	(4,329)	(4,141)	188
Total Expenditure	(10,115)	(9,924)	191	(10,115)	(9,924)	191
EBITDA	837	1,024	188	837	1,024	188

Appendix 8: statement of financial position

	Mar-20 £000's Actual	Feb-21 £000's Actual	Mar-21 £000's Actual	Movement £000's Actual
Non Current Assets				
Property, plant and equipment	529,792	544,781	564,714	19,933
Intangible assets	6,570	4,622	4,069	(553)
Trade and other receivables	3,825	1,959	1,914	(46)
TOTAL NON CURRENT ASSETS	540,187	551,363	570,697	19,334
Current Assets				
Inventories	21,940	21,806	19,152	(2,654)
Trade and other receivables	50,858	48,803	26,394	(22,409)
Cash and cash equivalents	16,016	145,548	90,033	(55,515)
TOTAL CURRENT ASSETS	88,814	216,157	135,578	(80,578)
Current Liabilities				
Trade and other payables	(72,531)	(78,382)	(112,913)	(34,531)
Borrowings (incl Finance Leases)	(359,299)	2	2	0
Accruals	(12,951)	(10,580)	(10,038)	542
Deferred Income	(7,411)	(93,968)	(1,862)	92,106
Dividend payable	(410)	(10,345)	(537)	9,809
Provisions for liabilities and charges	(6,704)	(11,855)	(13,533)	(1,679)
TOTAL CURRENT LIABILITIES	(459,306)	(205,128)	(138,881)	66,247
NET CURRENT ASSETS (LIABILITIES)	(370,492)	11,028	(3,303)	(14,331)
TOTAL ASSETS LESS CURRENT LIABILITIES	169,695	562,391	567,394	5,003
Non Current Liabilities				
Trade and other payables				
Finance Leases	(1,192)	(6,663)	(6,871)	(208)
Provisions for liabilities and charges	(4,933)	0	(3,056)	(3,056)
TOTAL NON CURRENT LIABILITIES	(6,125)	(6,663)	(9,927)	(3,264)
TOTAL ASSETS EMPLOYED	163,570	555,728	557,468	1,739
Public dividend capital	369,325	722,871	742,817	19,946
Revaluation reserve	168,342	168,342	168,342	0
Retained earnings	(374,098)	(335,485)	(353,692)	(18,206)
TOTAL TAXPAYERS EQUITY	163,570	555,728	557,468	1,739


The Statement of Financial Position (SOFP) at 31 March 2021 and movements from the previous month are presented in the table opposite, It should be noted that the opening and closing SOFP will change with further agreed adjustments from the review of the 2019/20 accounts

The key in month movements are as follows:

- **Non Current Assets**
 - PPE and Intangibles increased in value by £19.3m, as an acceleration of capital programme spend in March (£22.1m) was partially offset by in month depreciation and amortisation costs incurred (£2.8m)
- **Working Capital**
 - **Stock** – reduced by £2.7m as a consequence of removing materials management and ward drugs stock from the balance sheet, following agreement with external auditors.
 - **Trade and other Receivables** - reduction as a consequence of removing partially completed spells from accrued income (paid by commissioners) (£10.5m), settlement of final 2020/21 SLA invoices by HEE (£7.9m), LPT (£0.9m) and payment of previously accrued annual leave by NHSEI (£1.7m).
 - **Cash Balances** – reduced by £55.5m to £90m, reflecting movements in Appendix 9.
 - **Trade and other payables and accruals** – increased by £34m, the main components being; prior year PSF/FRF repayment liability (£10.9m), timing of capital creditors to be settled in the first quarter of 2021/22 (£7.6m), additional accrued annual leave accrued (£9.8m), and accrued liability for the working time directive implications of the Flowers Case (£2.2m).
 - **Deferred Income balances** - Reduced by £92.1m mainly due to release of March SLA patient care block contract income advanced in February and education and training LDA funding.
- **Provisions**
 - Provisions have increased by (£4.7m) driven mainly by revision of the section 106 liabilities relating to the Glenfield land swap (£2.2m), VAT liability relating to Commercial Trials and Business Activity advice from VAT Liaison (£1.9m), HR tribunals (£0.3m) and increase in pension tax provision (£0.4m).
- **Reserves**
 - PDC increased in line with the drawdown of agreed capital PDC funds (£19.9m)
 - The cumulative deficit on the I&E reserve increased in line with the in month deficit reported of £18.2m generated in March.

Appendix 9: cashflow forecast

Monthly cash flow £000	Annual	Actual YTD												Apr Forecast
		Apr	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar	
Receipts														
SLA block payments	948,782	155,510	77,843	77,767	77,755	77,755	77,755	77,304	77,374	73,257	80,512	81,399	14,551	66,552
COVID-19 top up	149,605	20,555	13,592	12,539	10,263	10,263	10,263	0	17,202	13,732	13,732	13,732	13,732	13,732
Health education payments	44,372	11,004	0	0	3,389	0	2,830	6,365	0	12,807	0	0	7,976	12,821
Other NHS income	67,030	10,836	6,080	7,801	2,697	3,512	3,383	3,518	5,947	3,986	2,898	5,305	11,067	9,450
PDC - capital	372,627	0	0	0	0	349,586	1,095	0	0	2,000	0	0	19,946	
TMP	39,122	3,470	3,131	2,486	3,185	3,284	2,726	3,299	3,906	3,660	3,140	3,727	3,109	2,918
Other non-NHS income	64,040	3,827	4,958	3,169	5,575	6,156	2,654	4,793	2,428	5,187	2,828	10,340	12,126	8,056
Total receipts	1,685,578	205,202	105,605	103,761	102,863	450,555	100,706	95,280	106,857	114,629	103,110	114,503	82,507	113,529
Salaries and wages	(691,972)	(55,409)	(57,033)	(57,778)	(57,742)	(57,466)	(57,549)	(57,885)	(57,059)	(58,668)	(58,271)	(58,347)	(58,764)	(58,802)
Creditor payments	(519,462)	(40,514)	(48,915)	(37,921)	(46,666)	(39,999)	(40,827)	(36,007)	(42,992)	(43,505)	(38,399)	(39,277)	(64,440)	(40,563)
PDC dividend	(12,699)	0	0	0	0	0	0	0	(1,949)	0	0	0	(10,750)	
Repayment of loans	(349,586)	0	0	0	0	(349,586)	0	0	0	0	0	0	0	
TMP	(38,387)	(4,265)	(2,445)	(2,322)	(3,353)	(2,876)	(2,539)	(3,692)	(3,736)	(4,284)	(2,861)	(2,132)	(3,882)	(3,053)
Total payments	(1,573,719)	(100,188)	(108,393)	(98,021)	(107,761)	(449,928)	(100,916)	(97,584)	(105,736)	(106,457)	(99,531)	(99,756)	(137,836)	(102,418)
Month end balance	111,859	105,014	(2,788)	5,740	(4,898)	627	(210)	(2,304)	1,121	8,172	3,579	14,747	(55,329)	11,111
Cash in transit and cash in hand adjustment	539	235	138	(328)	(124)	95	60	(71)	0	0	2,066	(1,573)	41	0
Balance brought forward	16,016	16,016	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,315	90,027
Balance carried forward	90,027	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,315	90,027	101,138
Month end cash balance	90,027	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,315	90,027	101,138



Cash balances reduced by £55.5m to £90m, as forecast at M11, mainly as a result of the Trust no longer receiving advanced SLA commissioner payments, an acceleration of creditor payments, in particular capital expenditure and the payment of the second installment of biannual PDC dividend. These cash reductions were partially mitigated by additional funding received from NHSEI to cover the annual leave provision and settlement of partially completed spells by commissioners. The Trust also received £20m of additional capital PDC funding. Cash is forecast to increase to £101m in April.

The Trust's underlying cash position is lower than the position reported currently. For example, there were a number of capital commitments made in March, which were not transacted as cash, but will be in Q1 in 2021/22. Although the Trust currently remains in a healthy cash position heading into the 2021/22 financial year, this will be challenged during 2021/22, as the NHS emerges from of Covid-19 block funding and the NHS as a whole returns to a normalised financial regime.

Appendix 10: working capital (1/2)

	Mar-20	Q1 YTD	Q2 YTD	Q3 YTD	Q4 YTD
Debtor and creditor days					
Debtor days	18	9	12	20	17
Creditor days	75	88	84	91	97

BPCC (cumulative)					
Value %	67%	92%	92%	93%	92%
Volume %	47%	92%	91%	89%	91%

BPCC (SMEs) paid within 30 days					
Value %	13%	92%	84%	90%	91%
Volume %	7%	93%	87%	86%	86%

BPCC (SMEs) paid within 5 days					
Value %	13%	24%	20%	59%	56%
Volume %	7%	28%	26%	24%	20%

BPPC

Performance has been broadly maintained across the year. Procure to pay financial improvement grip and control actions will be taken over the next 6 months to improve the performance towards the 95% target. A purchase to pay working group has been re-established to oversee the implementation of these actions.

Appendix 10: working capital (2/2)

	0 to 30 days	31 to 60 days	61 to 90 days	Over 90 days	Percentage over 90 days
March 2021	£000	£000	£000	£000	%
Non-NHS receivables	2,972	787	989	3,529	43%
NHS receivables	1,695	124	94	265	12%
Total receivables	4,667	911	1,083	3,794	36%
Bad debt provision					
Non-NHS payables	15,491	1,626	918	1,340	7%
NHS payables	1,970	399	597	1,972	40%
Total payables	17,461	2,025	1,515	3,312	14%

February 2021					
Non-NHS receivables	2,484	1,372	127	3,922	50%
NHS receivables	9,733	1,373	159	403	3%
Total receivables	12,217	2,745	286	4,324	22%
Bad debt provision					
Non-NHS payables	19,013	1,933	1,824	936	4%
NHS payables	2,544	1,411	579	2,862	39%
Total payables	21,557	3,344	2,403	3,798	12%

Aged Debt (Sales Ledger)

Overall sales ledger debt reduced by £9.1m to £10.5m, mainly associated with the settlement of HEE and LPT SLA invoices settled in March. Over 90 day debt levels reduced by £0.5m in March, mainly associated with the write off of old debts, in particular overseas outpatients, where recovery attempts have been exhausted.

It should be noted that £0.6m of the over 90 debt is currently on an instalment repayment plan, with 63% of outstanding over 90 days debt relating to overseas and private patients debt. A work stream has commenced and additional resources allocated to retrospectively recover and strengthen processes to ensure effective recovery of overseas and private patient debt going forward, as part of the Financial Improvement Plan.

Appendix 11: capital programme

Capital scheme	Full Year £000		
	Plan	Actual	Variance
Reconfiguration Scheme	3,627	3,905	278
ICU	7,893	7,984	91
EMCHC	11,723	11,461	(262)
Gynae scheme - ward 29	542	564	22
MEE 3T MRI Scanner	3,177	3,177	0
Medical Equipment	3,507	3,522	15
MES Replacement	316	278	(38)
MES Enabling Costs of MES	437	315	(122)
Additional medical equipment b/fwd	1,322	1,226	(96)
IM&T Infrastructure programme	1,991	2,092	101
IM&T eHospital	1,056	1,230	174
IM&T General	596	620	24
Digital Aspirant programme	501	501	0
HSLI	1,673	1,742	69
Cyber resilience	95	95	0
LIMS	537	437	(100)
iPads Videoconferencing	19	19	0
Covid IT	63	63	0
Critical Infrastructure Risk	4,263	4,263	0
Slippage / Backlog / Other	3,662	4,484	822
Linear Accelerator Bunker	164	313	149
E&F Breakdown fund - defined schemes	1,052	1,052	0
Backlog maintenance	600	600	0
Hope Expansion Project	720	917	197
E&F CAT3 Lab Sandringham	44	75	31
ED Scheme	1,615	1,178	(437)
SDEC	419	423	4
Car parking scheme ANPR	772	797	25
Glenfield rec hall refurbishment	400	489	89
Covid-19 - PDC funded	3,912	3,912	0
Other Covid related spend	3,120	2,394	(726)
Critical care wards	1,270	1,513	243
Endoscopy Scheme	3,233	3,629	396
ECMO Machines	180	180	0
eQuip	2,000	1,937	(63)
Other - donated	770	620	(150)
Other	3,716	275	(3,441)
Endoscopy training equipment	180	102	(78)
PMO office	198	327	129
Digital Pathology	101	101	0
Total	71,466	68,812	(2,654)

The capital expenditure position as at the end of March was £68.8m, which was £2.7m below the full year plan of £71.5m. All slippage has been identified and built into the 2021/22 capital programme.

The Trust received PDC funding of £21.8m, including £3.9m for Covid-19.

Funding source		£000
A	Internally generated depreciation	31,166
B	PDC	17,865
C	COVID-19 PDC	3,912
D	Finance lease	4,300
E	Other	11,569
Total		68,812